Mitopure is Timeline’s branded, pharmaceutical-grade form of urolithin A: a compound produced when gut bacteria metabolize ellagitannins found in pomegranates, walnuts, and certain berries. It has attracted serious scientific attention because of its proposed ability to trigger mitophagy, the cellular process that clears out damaged mitochondria and makes room for healthier replacements.
Mitopure is a premium supplement whose monthly costs vary by brand (see Amazon for current pricing) and by format. This review examines what peer-reviewed clinical evidence actually supports, where the research has meaningful gaps, and whether the product merits consideration for specific goals.
Key Takeaways
- Urolithin A is proposed to work by inducing mitophagy, mostly shown in cells and animals [8][9], the process of identifying and clearing damaged mitochondria, not as a simple antioxidant or stimulant.
- A randomized trial of 88 middle-aged adults, funded by the maker of Mitopure, missed its primary endpoint (peak cycling power); hamstring strength, a secondary endpoint, was higher on urolithin A than placebo [1].
- A 2025 randomized trial found urolithin A may also influence markers of age-related immune decline [2], broadening its potential relevance beyond muscle.
- Evidence in trained athletes is limited and mixed: a runners trial found no improvement in 3000 m time and an 8-week resistance trial reported it did not show improved muscle strength [3][4]; most trials are short-term and predominantly in male participants [3][4].
- Mitopure has more clinical backing than most longevity supplements, but it is not a substitute for exercise, diet, or medical care.
The Mechanism: Why Mitophagy Matters
Mitochondria are the energy-producing organelles inside nearly every cell. Over time they accumulate damage from oxidative stress and normal wear. Cells have a quality-control system called mitophagy, a selective form of autophagy, that identifies and breaks down dysfunctional mitochondria so new, healthier ones can take their place.
Urolithin A appears to activate mitophagy through signaling pathways that promote this renewal process. More efficient mitophagy means cells can maintain a higher proportion of functional mitochondria, which in theory translates to better energy production, reduced cellular stress, and improved tissue function over time. This is distinct from simple antioxidant supplementation: rather than neutralizing free radicals after the fact, urolithin A aims to improve the underlying quality of the mitochondrial pool.
In aged mice, a chestnut-flower extract that raised urolithin A (along with other compounds) improved muscle weight and grip strength; this is animal data and cannot be credited to urolithin A alone [5]. This gives the broader framework biological grounding and helps explain why urolithin A research has focused heavily on muscle health and age-related decline.
Clinical Evidence in Middle-Aged Adults
One of the most important human trials found that urolithin A supplementation improved muscle strength, exercise performance, and biomarkers of mitochondrial health in middle-aged adults in a randomized controlled trial [1]. Published in Cell Reports Medicine in 2022, this study showed that urolithin A can change some secondary measures in humans, though it did not meet its primary endpoint [1]not just in cell cultures or animal models.
The main Mitopure trial missed its primary endpoint; its gains were on secondary measures
Peak power output
The pre-specified primary endpoint, peak power on a cycling test, did not change significantly versus placebo.
Hamstring torque
Average peak torque rose 12% at 500 mg and 9.8% at 1,000 mg from baseline, with p = 0.027 and p = 0.029 versus placebo.
Peak VO2
It rose within the 1,000 mg group, but the comparison with placebo was p = 0.058, not conventionally significant.
CRP lower at both doses
The inflammation marker CRP fell at both doses, but the drop was statistically significant only at 1,000 mg.
Sponsored by Amazentis
Amazentis SA makes Mitopure, and several authors are its employees, board members or advisers.
Treat the strength signals as leads for future trials, not as proof that Mitopure works.
Randomized, placebo-controlled trial in 88 healthy middle-aged adults at a single site. Source: Singh et al., Cell Reports Medicine 2022.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: In the Cell Reports Medicine trial of 88 middle-aged adults, hamstring average peak torque changed by -9.8% on placebo versus 12% and 9.8% in the two urolithin A dose groups. The 12% figure is a change from baseline, and the lower dose did at least as well as the higher dose [1].
The mitochondrial biomarker findings are early signals only; plasma acylcarnitines fell at 500 mg but not at 1,000 mg, so the biomarker showed no dose-response [7][1]. Improvements in both biomarkers and functional outcomes like strength and exercise performance give the research more internal coherence than trials tracking only self-reported wellness.
It is worth noting that this study was conducted in middle-aged adults: a population where mitochondrial function is beginning to naturally decline. How well these findings translate to younger, healthy adults or to older adults with more significant mitochondrial dysfunction is not directly answered by this single trial.
One caveat: this trial’s pre-specified primary endpoint, peak power on a cycling test, did not change significantly versus placebo, and the sponsor was the company behind Mitopure. A second trial in 66 older adults (JAMA Network Open) also reported no significant improvement on its primary endpoints, and a 2024 systematic review of five human studies found no effect on physical function [1][10][11].
Urolithin A and Immune Health
Beyond muscle and energy, a 2025 randomized placebo-controlled trial published in Nature Aging investigated urolithin A’s effect on age-related immune decline [2]. The immune system undergoes measurable changes with aging, a process sometimes called immunosenescence, and mitochondrial dysfunction in immune cells is thought to contribute to this deterioration.
The findings suggest that the mitophagy-promoting mechanism may have relevance beyond skeletal muscle, adding another dimension to the potential value of supplementation for older adults. Immune benefits are harder to quantify in daily life than strength or endurance gains, and this remains an emerging area of inquiry. The trial was funded by the maker of Mitopure, and its main measures were shifts in immune cell subsets and cell metabolism rather than illness or clinical outcomes [2].
Evidence in Athletes and Physically Active People
More recent trials have examined urolithin A in physically trained populations. An 8-week randomized, double-blind, placebo-controlled study in male athletes undergoing resistance training assessed effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism [3]. This is important because trained individuals have different baseline mitochondrial profiles than sedentary middle-aged adults, and the question is whether supplemental mitophagy support provides a meaningful edge on top of exercise-induced adaptations.
A 2025 review of emerging evidence in sports nutrition noted that while preclinical findings are promising, the translation to athletic performance remains an active area of research [6]. More specifically, a 2025 randomized trial evaluated urolithin A supplementation on running performance, recovery, and mitochondrial biomarkers in highly trained male distance runners [4]. Research in elite populations is particularly demanding because performance plateaus are common and hard to shift.
The overall picture for athletes is cautiously optimistic. There is biological plausibility, growing clinical trial data, and no evidence of ergogenic harm, but effect sizes in trained populations appear more modest than in sedentary or aging adults, and most trials to date are short-term and conducted in male participants.
Honest Limitations of the Current Evidence
The evidence base for urolithin A is growing but still relatively small compared to better-studied supplements like creatine or vitamin D. Most trials have run for weeks to a few months; long-term effects of sustained supplementation are not well characterized. Whether benefits plateau, accumulate over years, or require any kind of cycling is unknown.
The majority of trials involve male participants, limiting how confidently findings can be applied to women. Older adults and people with clinically significant mitochondrial-related conditions are also underrepresented, despite being the population with arguably the most to gain. Additionally, not everyone produces urolithin A from dietary sources equally: gut microbiome differences mean some people are natural non-producers, which is part of the rationale for supplementing directly, but it also means individual responses will vary.
Most published research has used Mitopure itself, manufactured by Timeline (formerly Amazentis). The evidence is therefore somewhat brand-specific. Whether generic urolithin A products achieve equivalent bioavailability and biological effects is not established by independent research, and this is a legitimate consideration when evaluating lower-cost alternatives.
Is Mitopure Worth the Cost?
Mitopure’s premium price reflects both its proprietary manufacturing process and a genuine investment in clinical research: it is backed by more human trial data than most supplements in the longevity or cellular health space. The randomized trials so far show mixed results: primary endpoints were missed in both the Cell Reports Medicine and JAMA Network Open trials, with some secondary measures favouring urolithin A [1][10], with emerging data on immune function [2] and endurance performance [4].
For middle-aged adults concerned about age-related muscle decline, or for endurance athletes looking for evidence-based recovery support, Mitopure has a stronger scientific case than the majority of longevity supplements currently marketed. For young, healthy individuals with no particular mitochondrial stress or training demands, the value proposition is less clear: the clinical data simply does not yet address that population well.
As with any supplement, it is most sensibly viewed as one component of a broader approach that includes regular exercise, adequate sleep, and a diet rich in whole foods. Urolithin A does not replace the mitochondrial benefits of physical activity; at best, it may complement them.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The evidence for urolithin A is promising but still limited in scale: most trials are short-term, predominantly in male participants, and conducted in specific age groups; long-term safety and efficacy data are lacking. Mitopure is a dietary supplement, not a medication, and cannot prevent or treat any disease. Individuals who are pregnant, nursing, taking immunosuppressive medications, or managing a chronic illness should consult a qualified healthcare professional before use.
Frequently Asked Questions
What is Mitopure and how is it different from other urolithin A products?
Mitopure is Timeline’s proprietary, pharmaceutical-grade urolithin A, produced to defined purity standards and delivered at a specific dose. Most clinical trials cited for urolithin A have used Mitopure specifically [1], which means the evidence applies more directly to this product than to generic alternatives whose bioavailability has not been independently verified in human trials.
How does urolithin A actually work inside the body?
Urolithin A activates mitophagy: the selective autophagy process that identifies and degrades dysfunctional mitochondria so healthier ones can replace them. Research has linked robust autophagy activation to the preservation of skeletal muscle function during aging [5], providing biological context for why this mechanism may matter for muscle health and energy as people get older.
What does the research show for muscle strength and endurance?
A 2022 randomized controlled trial in middle-aged adults found that urolithin A improved muscle strength, exercise performance, and mitochondrial biomarkers compared to placebo [1]. A separate 8-week randomized study in male resistance-training athletes examined effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism [3], extending the findings toward more active populations.
Is there evidence for benefits beyond muscle health?
Yes, though early-stage. A 2025 randomized placebo-controlled trial in Nature Aging found that urolithin A influenced markers of age-related immune decline [2], suggesting the mitophagy mechanism may benefit immune cell function as well as skeletal muscle. This is a relatively new area of investigation and should be interpreted cautiously.
Does Mitopure improve athletic performance?
Evidence so far is limited. A 2025 randomized trial of highly trained male distance runners found no significant improvement in 3000 m time trial performance when it evaluated urolithin A on running performance, recovery, and mitochondrial biomarkers [4], and a 2025 review of sports nutrition evidence noted that the field is actively bridging preclinical findings to athletic applications [6]. Effect sizes in trained populations appear more modest than in aging or sedentary groups, and the research is still maturing.
Who is most likely to benefit from Mitopure?
Based on current evidence, middle-aged adults experiencing age-related decline in muscle function or energy are the best-studied population [1]. People concerned about immune aging may also have reason to consider it [2]. Young, healthy individuals with no particular mitochondrial stress are underrepresented in trials, and the cost-benefit is less clear for them. Anyone on medications or managing chronic health conditions should consult a qualified healthcare professional before starting.
References
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
- Zhao H et al. Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. Journal of the International Society of Sports Nutrition (2024). PMID 39487653
- Whitfield J et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Sports medicine (Auckland, N.Z.) (2025). PMID 40839339
- Park SH et al. A Natural Autophagy Activator Castanea crenata Flower Alleviates Skeletal Muscle Ageing. Journal of cachexia, sarcopenia and muscle (2025). PMID 39873130
- Wang M et al. Emerging evidence of Urolithin A in sports nutrition: bridging preclinical findings to athletic applications. Frontiers in nutrition (2025). PMID 40453722
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Peter M. J. Quinn et al. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathologica Communications (2020). PMID 33168089
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.